Startseite>>Signaling Pathways>> Tyrosine Kinase>> EGFR>>AZD3759

AZD3759 (Synonyms: AZD3759)

Katalog-Nr.GC13143

AZD3759 (AZD3759) ist ein potenter, oral aktiver, das Zentralnervensystem durchdringender EGFR-Inhibitor. Bei Km-ATP-Konzentrationen betragen die IC50-Werte 0,3, 0,2 bzw. 0,2 nM fÜr EGFRwt, EGFRL858R und EGFRexon 19Del.

Products are for research use only. Not for human use. We do not sell to patients.

AZD3759 Chemische Struktur

Cas No.: 1626387-80-1

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
48,00 $
Auf Lager
5 mg
42,00 $
Auf Lager
10 mg
54,00 $
Auf Lager
50 mg
108,00 $
Auf Lager
100 mg
171,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

AZD3759 is a potent and oral active inhibitor of EGFR (IC50= 7.0-7.7 nM) with antineoplastic activity.

EGFR (epidermal growth factor receptor) is a cell-surface receptor tyrosine kinase. The receptor activation leads to dimerization and tyrosine autophosphorylation. It induces a cascade of downstream cellular responses such as modification in gene expression, cell proliferation and cytoskeletal rearrangement etc.

AZD3759 shows equally potent inhibitory effect on cell phosphorylation or proliferation in EGFR-activating mutant cell lines (PC-9 and H3255) in the range of 7.0−7.7nM. In cellular phosphorylation assays, AZD3759 also exhibits 9-fold inhibition selectivity in EGFR-activating

mutant cell lines over EGFR wild-type cell lines (H838). [1]

In brain metastasis mouse model, AZD3759 demonstrates prominent antitumor efficacy in a dose dependent manner (∼78% tumor growth inhibition at 7.5 mg/kg qd and tumor regression at 15 mg/kg qd, respectively, 4 weeks after treatment, with <20% body weight loss). In addition, at the doses of 7.5 and 15 mg/k, AZD3759 significantly decreases tumor area in the brain tissue collected from the same mouse model. [1]

Reference:
Zeng Q, Wang J, Cheng Z et al.  Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. J Med Chem. 2015 Oct 22;58(20):8200-15

Bewertungen

Review for AZD3759

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AZD3759

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.